Letters

Future of research into rotavirus vaccine

BMJ 2001; 322 doi: https://doi.org/10.1136/bmj.322.7278.106/a (Published 13 January 2001) Cite this as: BMJ 2001;322:106

Cost effectiveness of vaccine is being assessed

  1. Damian Walker (damian.walker@lshtm.ac.uk), research fellow in health economics,
  2. S M Akramuzzaman, senior medical officer,
  3. Claudio F Lanata, senior researcher
  1. Health Policy Unit, London School of Hygiene and Tropical Medicine, London WC1E 7HT
  2. Clinical Sciences Division, ICDDR,B: Centre for Health and Population Research, GPO Box 128, Dhaka 1000, Bangladesh
  3. Instituto de Investigación Nutricional, Apartado 18-0191, Lima-18, Peru
  4. Instituto de Biomedicina, Ministerio de Sanidad y Desarrollo Social, Universidad Central de Venezuela, AP 4043, Carmelitas, Caracas 1010A, Venezuela

    EDITOR—Weijer states that the benefits of rotavirus vaccine may outweigh risks for children in developing countries.1 The issue of cost effectiveness is therefore central to the choice of whether developing countries should adopt a rotavirus vaccine. We are involved in a project funded by the United Kingdom's Department for International Development that will model the impact and incremental cost effectiveness of introducing a rotavirus vaccine into routine infant immunisation programmes in Bangladesh and Peru.

    Frequently, poor families in developing countries must sell assets at a loss, or take out loans at high interest rates, to pay for care.2 Hence optimising the use of vaccines will increase the potential for economic development of the poorest groups by reducing their out of pocket costs of obtaining treatment, especially for more severe disease. Governments also stand to benefit through reducing the burden on frequently overstretched …

    View Full Text

    Sign in

    Log in through your institution

    Subscribe